

Dennis W Lendrem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/607044/publications.pdf>

Version: 2024-02-01

86
papers

2,253
citations

304602

22
h-index

243529

44
g-index

99
all docs

99
docs citations

99
times ranked

3115
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Sjögren's syndrome: Longitudinal real-world, observational data on health-related quality of life. <i>Journal of Internal Medicine</i> , 2022, 291, 849-855.	2.7	9
2	Key reaction components affect the kinetics and performance robustness of cell-free protein synthesis reactions. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 218-229.	1.9	4
3	Why stratification is important in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2022, , 1.	1.5	0
4	Comorbidities in the UK Primary Sjögren's Syndrome Registry. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
5	Interferon- γ -mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1214-1223.	0.5	18
6	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. <i>Lancet Rheumatology</i> , The, 2021, 3, e9-e10.	2.2	9
7	COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 6.	1.3	21
8	SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 636160.	1.2	13
9	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021, 41, 1593-1600.	1.5	13
10	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. <i>Clinical Proteomics</i> , 2021, 18, 20.	1.1	2
11	Schrödinger's pipeline and the outsourcing of pharmaceutical innovation. <i>Drug Discovery Today</i> , 2020, 25, 480-484.	3.2	4
12	In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 621-630.	1.3	9
13	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091532.	1.2	6
14	Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2020, 40, 541-548.	1.5	22
15	First experience of COVID-19 screening of health-care workers in England. <i>Lancet</i> , The, 2020, 395, e77-e78.	6.3	261
16	Exploring medicines reconciliation in the emergency assessment unit: staff perceptions and actual waiting times. <i>Emergency Nurse</i> , 2020, 28, 28-33.	0.1	0
17	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. <i>Journal of Autoimmunity</i> , 2019, 105, 102298.	3.0	34
18	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. <i>Rheumatology International</i> , 2019, 39, 1867-1873.	1.5	35

#	ARTICLE	IF	CITATIONS
19	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	2.2	76
20	<p>Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions</p>. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 77-88.	0.8	19
21	Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. <i>Pharmaceutical Statistics</i> , 2019, 18, 632-635.	0.7	2
22	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome. <i>RMD Open</i> , 2019, 5, e000885.	1.8	14
23	Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists. <i>Pharmaceutical Statistics</i> , 2019, 18, 402-406.	0.7	8
24	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. <i>Rheumatology</i> , 2019, 58, 1250-1258.	0.9	14
25	Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients. <i>Rheumatology</i> , 2019, 58, 1268-1273.	0.9	13
26	AB1287–DISEASE EVOLUTION OF PRIMARY SJOGREN’s SYNDROME – A LONGITUDINAL STUDY. , 2019, , .		0
27	OP0202–EFFECT OF RSLV-132 ON FATIGUE IN PATIENTS WITH PRIMARY SJöGREN’s SYNDROME – RESULTS OF A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY. , 2019, , .		3
28	FRI0652–SERUM CXCL13 LEVELS ARE ASSOCIATED WITH LYMPHOMA RISK AND LYMPHOMA OCCURRENCE IN PRIMARY SJöGREN’s SYNDROME. , 2019, , .		1
29	FRI0009–MOLECULAR PROFILING OF CIRCULATING B-LYMPHOCYTES REVEALS THE SUPERIOR PERFORMANCE OF METHYLOME OVER TRANSCRIPTOME DATA FOR DISCRIMINATING RHEUMATOID ARTHRITIS PATIENTS IN AN EARLY ARTHRITIS CLINIC: IMPLICATIONS FOR TRANSLATING “BIG DATA” INTO CLINICALLY USEFUL TOOLS. , 2019, , .		0
30	Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren’s syndrome: a randomized-controlled trial. <i>Rheumatology International</i> , 2019, 39, 227-238.	1.5	20
31	Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. <i>Rheumatology</i> , 2018, 57, 921-930.	0.9	102
32	The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 445-448.e4.	1.5	41
33	CD4+ and B Lymphocyte Expression Quantitative Traits at Rheumatoid Arthritis Risk Loci in Patients With Untreated Early Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 361-370.	2.9	37
34	The RA-MAP Consortium: a working model for academia–industry collaboration. <i>Nature Reviews Rheumatology</i> , 2018, 14, 53-60.	3.5	15
35	O08–f Additive value of a fifteen-minute ultrasound screen to clinical predictors of an inflammatory diagnosis warranting DMARDs in an early arthritis clinic. <i>Rheumatology</i> , 2018, 57, .	0.9	0
36	Physical activity but not sedentary activity is reduced in primary Sjögren’s syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	1.5	16

#	ARTICLE	IF	CITATIONS
37	01.10â€¦Peripheral blood plasmacytoid dendritic cells in early rheumatoid arthritis. , 2017, , .		0
38	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. Arthritis Care and Research, 2017, 69, 1714-1723.	1.5	18
39	A scoping exercise to gauge the incidence of early post-stroke fatigue for patients at Newcastle community stroke services. International Journal of Therapy and Rehabilitation, 2017, 24, 52-52.	0.1	2
40	05.10â€¦Comparison of cd4+ and b lymphocyte expression quantitative trait associations at ra risk loci in untreated early arthritis patients. , 2017, , .		0
41	125.â€¦HOW TO EXPAND AWARENESS OF AND RECRUITMENT TO RESEARCH: A MIXED METHODS FEASIBILITY STUDY. Rheumatology, 2017, 56, .	0.9	1
42	261.â€¦CD4+ T CELL EXPRESSION QUANTITATIVE TRAIT EFFECTS AT RHEUMATOID ARTHRITIS RISK LOCI DIFFER SIGNIFICANTLY BETWEEN EARLY ARTHRITIS DISEASE PHENOTYPES: IMPLICATIONS FOR PATHOGENESIS. Rheumatology, 2017, 56, .	0.9	0
43	109â€¦Experiences of Staff and Patients in Relation to Clinical Research Recruitment and Involvement: A Qualitative Study. Rheumatology, 2016, , .	0.9	0
44	289â€¦A Cytokine-Mediated Biological Basis for Fatigue in Primary Sjögren's Syndrome. Rheumatology, 2016, 55, i179-i179.	0.9	1
45	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology, 2016, 55, 1843-1848.	0.9	23
46	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open, 2016, 2, e000282.	1.8	77
47	Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecy. Pharmaceutical Statistics, 2016, 15, 90-92.	0.7	5
48	Gainâ€¦ofâ€¦function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). European Journal of Immunology, 2015, 45, 2834-2846.	1.6	111
49	Lost in space: design of experiments and scientific exploration in a Hogarth Universe. Drug Discovery Today, 2015, 20, 1365-1371.	3.2	20
50	Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery, 2015, 14, 219-221.	21.5	12
51	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. Rheumatology, 2015, 54, 655-659.	0.9	22
52	Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology, 2015, 54, 374-375.	0.9	4
53	Why is it hard to terminate failing projects in pharmaceutical R&D?. Nature Reviews Drug Discovery, 2015, 14, 663-664.	21.5	46
54	R&D productivity rides again?. Pharmaceutical Statistics, 2015, 14, 1-3.	0.7	20

#	ARTICLE	IF	CITATIONS
55	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. PLoS ONE, 2015, 10, e0143970.	1.1	45
56	The UK Primary Sjögren's Syndrome Registry (UKPSSR): A Valuable Resource for Future Sjögren's Syndrome Research. Rheumatology, 2014, 53, i136-i136.	0.9	0
57	The Darwin Awards: sex differences in idiotic behaviour. BMJ, The, 2014, 349, g7094-g7094.	3.0	20
58	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Annals of the Rheumatic Diseases, 2014, 73, 1362-1368.	0.5	87
59	The development speed paradox: can increasing development speed reduce R&D productivity?. Drug Discovery Today, 2014, 19, 209-214.	3.2	8
60	Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sjögren's syndrome: a mixed-methods study protocol. BMJ Open, 2014, 4, e006264-e006264.	0.8	6
61	Soluble molecule profiling and network analysis of primary Sjögren's Syndrome patient serum. BMC Musculoskeletal Disorders, 2013, 14, .	0.8	1
62	Torching the Haystack: modelling fast-fail strategies in drug development. Drug Discovery Today, 2013, 18, 331-336.	3.2	11
63	Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren's syndrome. BMJ Open, 2013, 3, e002739.	0.8	8
64	FRI0448...Evaluating health status of 620 patients with primary sjögren's syndrome using EQ-5D. Annals of the Rheumatic Diseases, 2013, 71, 466.1-466.	0.5	0
65	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2012, 71, 1973-1979.	0.5	57
66	Impaired functional status in primary Sjögren's syndrome. Arthritis Care and Research, 2012, 64, 1760-1764.	1.5	62
67	Dose Regimen Adjustment for Milrinone in Congestive Heart Failure Patients with Moderate and Severe Renal Failure. Journal of Pharmacy and Pharmacology, 2011, 47, 651-655.	1.2	24
68	Statistical support to non-clinical. Pharmaceutical Statistics, 2002, 1, 71-73.	0.7	8
69	DOE (Design of Experiments) in Development Chemistry: Potential Obstacles. Organic Process Research and Development, 2001, 5, 324-327.	1.3	59
70	Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemotherapy and Pharmacology, 1997, 40, 1-10.	1.1	37
71	Analysis of Variance in Experimental Design.. Journal of the Royal Statistical Society: Series D (the Tj ETQq1 1 0.784314 rgBT/Overlo	0.2	0
72	Categorical Data Analysis.. Journal of the Royal Statistical Society: Series D (the Statistician), 1991, 40, 457.	0.2	2

#	ARTICLE	IF	CITATIONS
73	Use of Statistical Experimental Design in Laboratory Scale Formulation Optimisation and Progression to Plant Scale. <i>Drug Development and Industrial Pharmacy</i> , 1991, 17, 2341-2358.	0.9	5
74	Scanning for predators in the purple sandpiper; a time-dependent or time-independent process?. <i>Animal Behaviour</i> , 1986, 34, 1577-1578.	0.8	28
75	Mathematical Methods. , 1986, , 7-34.		0
76	Games Theory Models: Social Behaviour. , 1986, , 162-195.		0
77	Statistical Testing in Dermatoglyphic Studies. <i>Human Heredity</i> , 1985, 35, 271-272.	0.4	0
78	Kinship affects puberty acceleration in mice (<i>Mus musculus</i>). <i>Behavioral Ecology and Sociobiology</i> , 1985, 17, 397-399.	0.6	13
79	Gulls and plovers: host vigilance, kleptoparasite success and a model of kleptoparasite detection. <i>Animal Behaviour</i> , 1985, 33, 1318-1324.	0.8	20
80	Vigilance and scanning patterns in birds. <i>Animal Behaviour</i> , 1984, 32, 1216-1224.	0.8	98
81	Sleeping and vigilance in birds. II. An experimental study of the Barbary dove (<i>Streptopelia risoria</i>). <i>Animal Behaviour</i> , 1984, 32, 243-248.	0.8	108
82	Flocking, feeding and predation risk: Absolute and instantaneous feeding rates. <i>Animal Behaviour</i> , 1984, 32, 298-299.	0.8	59
83	Predation risk and vigilance in the blue tit (<i>Parus caeruleus</i>). <i>Behavioral Ecology and Sociobiology</i> , 1983, 14, 9-13.	0.6	151
84	Sleeping and vigilance in birds. I. Field observations of the mallard (<i>Anas platyrhynchos</i>). <i>Animal Behaviour</i> , 1983, 31, 532-538.	0.8	79
85	Vigilance of a Nest-building Female Blue Tit (<i>Parus caeruleus</i>). <i>Zeitschrift für Tierpsychologie</i> , 1980, 54, 279-284.	0.2	3
86	215. Cognitive Impairment in Primary Sjögren's Syndrome. <i>Rheumatology</i> , 0, , .	0.9	0